Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115293 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
A Phase 3 study, sponsored by Ra Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 174
- Enrollment target
NCT04115293 is a Phase 3 study that has completed, run by Ra Pharmaceuticals. The registered enrollment target is 174 participants.
The verdict
NCT04115293, a Phase 3 study, has completed, sponsored by Ra Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 174 participants
- Enrollment target
Study Summary
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Interventions
- DRUG Placebo
- DRUG zilucoplan (RA101495)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2019-09-17 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04115293
The ClinicalTrials.gov registry entry for NCT04115293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ra Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04115293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04115293 about?
NCT04115293 is a clinical study titled "Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis". The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo...
What is the current status of trial NCT04115293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 174 participants. The study started on 2019-09-17. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04115293?
The interventions under investigation include: Placebo (DRUG), zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT04115293?
This trial is sponsored by Ra Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.